Masimo Corporation announced its financial results for the second quarter ended June 28, 2025, on August 5, 2025. The core Healthcare business delivered $370 million in revenue, representing 7.4% growth on a constant currency basis.
Non-GAAP diluted earnings per share for Q2 2025 was $1.33, marking a 46% increase over the prior year. CEO Katie Szyman highlighted the strong growth and earnings of the healthcare business, driven by operational improvements and commercial excellence.
The company reaffirmed its fiscal year 2025 guidance, projecting Healthcare revenue of $1.505 billion to $1.535 billion, an 8% to 11% constant currency growth. Full-year EPS is projected to be in the range of $5.20 to $5.45, with the estimated tariff impact for 2025 successfully reduced by over 50% to $17 million-$19 million from original projections.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.